Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in advanced tumors
NCT02407990Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jun 2015
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of tislelizumab in solid tumor (advanced stage) (2 arms), sponsored by BeiGene. Primary endpoints: Number of Participants Experiencing Adverse Events (AEs), Number Of Participants With Abnormal Physical Examination Values and 5 more. Started Jun 2015; status: completed.
02
Drugs
tislelizumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02407990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02407990.